After 30 years of research, pill developed at Duke for breast cancer approved for use After six years of painful injections, Stephanie Walker has had enough. Tribune News Service · Feb 8, 2023
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health… Benzinga · Aug 11, 2022
Merger Arbitrage Mondays - Zendesk To Be Acquired By Permira and Hellman & Friedman Editor's Note: Starting next month, we will be rolling the Merger Arbitrage Mondays series into our paid subscription services, Inside Arbitrage Plus and Inside Arbitrage Premium. The more affordable Plus service focuses on content including a monthly special situations newsletter, a model portfolio and mid-month updates. The Premium service includes both… Benzinga · Jun 27, 2022
4 Analysts Have This to Say About Radius Health Analysts have provided the following ratings for Radius Health (NASDAQ:RDUS) within the last quarter: Benzinga · Jun 24, 2022
Bone Health Focused Radius Health Goes Private In $890M Deal Radius Health Inc (NASDAQ:RDUS) will be acquired by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million, including the assumption of debt and assuming full payment of the CVR (Contingent Value Right). Gurnet Point and Patient Square will pay $10.00 per share in cash plus a… Benzinga · Jun 23, 2022
Radius Health's Return On Capital Employed Insights Radius Health (NASDAQ:RDUS) brought in sales totaling $43.16 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 17.27%, resulting in a loss of $18.28 million. Benzinga · May 31, 2022
Recap: Radius Health Q1 Earnings Radius Health (NASDAQ:RDUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Benzinga · May 5, 2022
How To Attend Radius Health Q1 2022 Earnings Conference Call Radius Health (NASDAQ:RDUS) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Radius Health (RDUS) Conference Call Follow this link to access the live webcast. Benzinga · Apr 29, 2022
Radius Health: A Biotech Stock Worth Buying Now? With continuing investments in research and development to extend human lifespans and improve the quality of life, the biotech industry looks poised for growth. RDUS is a fundamentally strong player in this space. So, let’s discuss if it is wise to bet on the name amid the current market volatility.… StockNews.com · Apr 13, 2022